Vidal prompts PTAB review of Spruce patents

In a win for Neurocrine, the Patent Trial and Appeal Board has decided to review Spruce’s endocrine patents after the USPTO director intervened.

Emcure prevails against ‘fairytale’ accusations

A US biotech has failed in its bid to secure $950m in damages from an Indian generic drug maker in a dispute over COVID-19 vaccine technology.

Cassels’ new hires ‘elevate’ IP offering across US

Two new partners, who have been appointed at the Canadian law firm’s Toronto office, bring ‘extensive’ track records of success in complex patent litigation.

Daiichi Sankyo secures nearly $46m legal fees

The final award denies all claims levied at the company in a dispute involving antibody drug technology.

The new IP battleground in CRISPR-Cas

The new IP battleground in CRISPR-Cas

Recent clashes over patents covering modified guide RNAs have exposed different approaches from the US and Europe—and new complications for the field, says Claire Irvine of HGF.

More features

Latest news

Emcure prevails against ‘fairytale’ accusations

05-12-2023

Emcure fends off COVID-19 trade secrets suit in Washington | A US biotech had inked a short-lived deal with Indian generic pharma company’s subsidiary.

US biotech wins review of rival’s endocrine patents after Vidal intervention

05-12-2023

Cassels’ new hires ‘elevate’ IP offering across US

05-12-2023

Daiichi Sankyo secures nearly $46m legal fees in antibody arbitration

30-11-2023

Life sciences cases taking centre stage at the UPC

28-11-2023

Teva and Eli Lilly end patent clash over migraine drug

28-11-2023

More news

Regions

Sectors

LSIPR